Amsterdam, the Netherlands, February 5, 2014 - uniQure B.V. ("uniQure"), a leader in human gene therapy, today announced the pricing of its initial public offering of 5,400,000 ordinary shares at an initial public offering price of $17.00 per ordinary share. In addition, uniQure has granted the underwriters a 30-day option to purchase up to an additional 810,000 ordinary shares from uniQure at the public offering price, less underwriting discounts. After deducting the underwriting discounts and other estimated offering expenses payable by uniQure, the net proceeds of the initial public offering are expected to be approximately $81.9 million. The offering is expected to close on or about February 10, 2014, subject to customary closing conditions. uniQure's ordinary shares have been approved for listing on the NASDAQ Global Select Market and are expected to begin trading under the symbol "QURE" onFebruary 5, 2014.
Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers for the offering. Piper Jaffray & Co. is acting as lead manager for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 4, 2014. The offering will be made only by means of a prospectus, copies of which may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, or by email at [email protected]
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
uniQure is delivering on the promise of gene therapy through single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease-modifying therapies to patients with severe disorders. We are engaged in multiple partnerships and have obtained regulatory approval of our lead product, Glybera, in the European Union for a subset of patients with LPLD.